Free shipping on all orders over $ 500

LNP023 hydrochloride (Iptacopan HCl)

Cat. No. M10317

All AbMole products are for research use only, cannot be used for human consumption.

LNP023 hydrochloride (Iptacopan HCl) Structure
Synonym:

Iptacopan hydrochloride

Size Price Availability Quantity
1mg USD 180 In stock
5mg USD 380 In stock
10mg USD 650 In stock
25mg USD 1050 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Iptacopan (LNP023) hydrochloride is an orally bioavailable, highly potent and selective factor B inhibitor with an IC50 value of 10 nM. Iptacopan (LNP023) shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM. LNP023 exhibits excellent selectivity over other proteases affording IC50 values of >30 μM across a panel of 41 human proteases, including the AP protein factor D (>100 μM).

In vivo, LNP023 (20-180 mg/kg; oral) prevents KRN (150 μL)-induced arthritis in mice and is effective upon prophylactic and therapeutic dosing in an experimental model of membranous nephropathy in rats.

Chemical Information
Molecular Weight 458.98
Formula C25H31ClN2O4
CAS Number 1646321-63-2
Solubility (25°C) DMSO ≥ 90 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Nello Mainolfi, et al. J Med Chem. Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases

[2] Anna Schubart, et al. Proc Natl Acad Sci U S A. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases

[3] Dimitrios C Mastellos, et al. Semin Hematol. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Related Complement System Products
Eculizumab

Eculizumab is a first-in-class recombinant humanized monoclonal antibody targeting complement protein C5. C5, which can only recognize humans, cannot bind to C5 of other species.

SB290157 trifluoroacetate salt

SB290157 is a selective antagonist of complement anaphylatoxin C3a receptor, a 74 amino acid proinflammatory peptide that is a potent chemotaxin for eosinophils, macrophages and mast cells.

JPE-1375

JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist. JPE-1375 effectively inhibits polymorphonuclear leukocyte mobilization (EC50=6.9 µM) and reduces TNF levels (EC50=4.5 µM) in mice.

Compstatin

Compstatinis is a 13-residue cyclic peptide, binds to complement component C3 and inhibits complement activation with IC50 of 12 μM. Compstatin exhibits exclusive specificity for primate C3s and does not bind either to C3s from lower mammalian species or to two structural homologs of C3, human C4 and C5.

Avacopan

Avacopan (CCX168) is a first-in-class, potent, selective and orally available complement 5a receptor (C5aR1 or CD88) antagonist with an IC50 of 0.1 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: LNP023 hydrochloride (Iptacopan HCl), Iptacopan hydrochloride supplier, Complement System, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.